8 Weeks
5 mg Vial- VialsCJC-1295 DAC + Ipamorelin Stack mg vials
- 4
- U-100 Syringesone sterile syringe per dose
- 12
- BAC Water30 mL multi-dose vials
- 1
- Alcohol Padsvial stopper + skin prep
- 20
8 total doses over 8 weeks
CJC-1295 with DAC (Weekly) + Ipamorelin (Daily) Dual-Vial Stack
A separate-vial growth-hormone secretagogue stack pairing once-weekly CJC-1295 with DAC (2 mg or 5 mg vial) for baseline GHRH elevation alongside daily Ipamorelin (5 mg vial) for targeted nocturnal GH pulses.
CJC-1295 DAC + Ipamorelin Stack Reference VialSelect your vial strength to update all reference concentrations, dosage tables, and syringe draws on this page.
Arithmetic summary: Reconstituting a 5 mg CJC-1295 DAC + Ipamorelin Stack vial with 1 mL of bacteriostatic water yields 5 mg/mL. Every 10 units (0.10 mL) on a U-100 insulin syringe delivers 500 mcg.
CJC-1295 DAC + Ipamorelin Stack · 5 mg VialArithmetic summary: Reconstituting a 10 mg CJC-1295 DAC + Ipamorelin Stack vial with 2 mL of bacteriostatic water yields 5 mg/mL. Every 10 units (0.10 mL) on a U-100 insulin syringe delivers 500 mcg.
CJC-1295 DAC + Ipamorelin Stack · 10 mg VialSelect a row to preview the draw on the syringe. Values are reference figures from the literature, not medical advice.
| Phase | Dose | mL | Units | Doses/Vial |
|---|---|---|---|---|
| BeginnerOnce weekly · Weeks 1–2 | 1 mg | 0.20 | 20 | 5 |
| StandardOnce weekly · Weeks 3–4 | 1.5 mg | 0.30 | 30 | 3 |
| TargetOnce weekly · Weeks 5–8+ | 2 mg | 0.40 | 40 | 2 |
| Phase | Dose | mL | Units | Doses/Vial |
|---|---|---|---|---|
| BeginnerOnce weekly · Weeks 1–2 | 1 mg | 0.20 | 20 | 10 |
| StandardOnce weekly · Weeks 3–4 | 1.5 mg | 0.30 | 30 | 6 |
| TargetOnce weekly · Weeks 5–8+ | 2 mg | 0.40 | 40 | 5 |
U-100 syringe drawn to 20 units (0.20 mL), 1 mg.
Dose exceeds this syringe's capacity. Choose a larger syringe or reduce the diluent volume.
Click any dosing tier row above to preview that exact draw on the U-100 syringe scale.
Four steps, in order. Work on a clean surface with washed hands and swab every vial top with alcohol first.
Step 01Draw 1 mL of bacteriostatic water (0.9% benzyl alcohol) into a sterile syringe. Use bacteriostatic, not plain sterile water, so the multi-dose vial stays preserved between draws.
Step 02Pierce the stopper and angle the needle at 45° so the water runs slowly down the inside glass wall. Never spray directly onto the lyophilized puck: the jet foams the solution and can denature fragile peptide chains.
Step 03Roll the vial gently between your fingers or swirl in a slow circle until the liquid is 100% clear with no undissolved particles. Shaking shears peptide bonds and traps air bubbles; if it clouds, let it rest in the fridge for 15 minutes.
Step 04Write the reconstitution date and concentration on the vial. Refrigerate upright at 2–8 °C (36–46 °F), protected from light, and use within 28–30 days. Do not freeze the reconstituted liquid.
Convert a lyophilized peptide vial amount and bacteriostatic water volume into a reconstitution concentration, then translate your protocol dose and schedule into exact U-100 syringe units and multi-week vial supplies.
Enter the peptide amount in the vial and the volume of bacteriostatic or sterile water you plan to add.
Concentration
How much peptide each mL of solution contains after mixing.
5 mg/mL
Enter the dose from your protocol, select your dosing schedule, and pick the insulin syringe you are using.
100-unit (1 mL): marks every 2 units. Standard barrel for draws up to 100 units.
Draw to
Pull plunger seal to line 5
Volume
0.05 mL
Delivers 250 mcg
Doses per vial
20
Lasts 20 days (Once daily)
4-Week Schedule Supply
2 vials
28 doses · 2.0 mL BAC water
| Duration | Total Peptide | Vials Required | U-100 Syringes | BAC Water |
|---|
For educational and research calculations only. Always confirm calculations independently before use.
Plan vials, U-100 insulin syringes, bacteriostatic water, and sterile alcohol prep pads by protocol duration.

CJC-1295 DAC + Ipamorelin Stack Vials (5 mg each):
U-100 Insulin Syringes & Alcohol Pads:
8 total doses over 8 weeks
12 total doses over 12 weeks
16 total doses over 16 weeks

CJC-1295 DAC + Ipamorelin Stack Vials (10 mg each):
U-100 Insulin Syringes & Alcohol Pads:
8 total doses over 8 weeks
12 total doses over 12 weeks
16 total doses over 16 weeks
Synergistic Protocols
Common research and clinical combinations pairing CJC-1295 DAC + Ipamorelin Stack with complementary pathways.
Pairs a GHRH analog (amplifying pulse peak) with a selective ghrelin mimetic (initiating pulse release without cortisol or prolactin spikes).
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| CJC-1295 (No DAC) | 100–200 mcg per injection | Nightly before bed (90+ min fasted) |
| Ipamorelin | 100–200 mcg per injection | Co-administered nightly (optional AM fasted pulse) |
Stacking Note: Carbohydrates and dietary fats blunt GH release; administer at least 90–120 minutes after your final evening meal.
Combines FDA-studied GHRH analog Tesamorelin (selective trunk/visceral adipose lipolysis) with a nighttime Ipamorelin pulse.
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| Tesamorelin | 1.0–2.0 mg once daily | Morning fasted or pre-bed SubQ |
| Ipamorelin | 100–200 mcg once daily | Pre-bed fasted SubQ |
Stacking Note: Monitor fasting glucose and serum IGF-1 levels at baseline and week 8.
Systemic GH/IGF-1 elevation upregulates collagen synthesis while BPC-157 increases local growth hormone receptor expression on fibroblasts.
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| Sermorelin or CJC-1295/Ipamorelin | 200–300 mcg nightly | Pre-bed fasted SubQ |
| BPC-157 | 250–500 mcg daily | Morning or post-training SubQ |
Stacking Note: One of the most widely studied clinical combinations for post-surgical and athletic soft-tissue recovery.
Rotate sites with every injection so no single area is used twice in a row. Swab with alcohol and let it dry for 10 seconds before injecting.

Zone 01
Abdomen
≥ 2 in away from navel
Zone 02
Outer Thigh
Middle third, anterior-lateral
Zone 03
Upper Arm
Posterior / outer tricep pad
90° · 4–8 mm (31 G) short needle
Standard U-100 insulin syringe: pinch a light fold and insert straight in at 90°.
45° · 12.7 mm (1/2 in) needle
Longer needle or leaner area: pinch a 1-inch fold and enter at 45° into fat.
Aseptic Injection Checklist
• Use a brand-new sterile U-100 syringe for every draw (never reuse needles).
• Swab both the vial rubber stopper and injection site with 70% isopropyl alcohol and let dry.
• Rotate clockwise around the abdomen or alternate left/right thigh to prevent lipohypertrophy.
Lyophilized Powder (Unmixed)
Freezer −20 °C Long-Term · Fridge Short-Term
Unmixed freeze-dried vials stay stable for months in the refrigerator and 1–2+ years at −20 °C (0 °F) in the dark. Let the vial warm to room temperature before opening.
Reconstituted Liquid (Mixed)
Refrigerate 2–8 °C (36–46 °F) · Use Within 30 Days
Keep refrigerated and out of light once mixed with bacteriostatic water. Never freeze reconstituted liquid — ice crystals shear the dissolved peptide chains.
Pharmacology & Evidence
How It Works
Separates the long-acting albumin-bound CJC-1295 DAC weekly injection from short-acting daily Ipamorelin pulses so each compound is dosed according to its true half-life.
subcutaneous
1-2mg CJC-DAC + 200mcg Ipamorelin · Weekly + Daily
8-12 weeks
Research use only. Not medical advice.
Demonstrated dose-dependent biological activity and target pathway engagement in published research studies
Research compound; not FDA-approved for general clinical use unless otherwise noted. Verify third-party COA purity and consult a licensed physician.
Clinical Profile
Provider Directory
Supplied as lyophilized powder in sterile multi-dose vials. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) and verify batch purity via HPLC and mass spectrometry COA.
Free Guide
New studies, regulatory changes and sourcing notes on the peptides you follow. One email a week, no spam.
Free. No spam. Unsubscribe anytime. From GLP1Search.
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides